Share This Article:

Survivin promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer

DOI: 10.4236/abb.2013.41001    3,906 Downloads   6,130 Views   Citations

ABSTRACT

Survivin is an inhibitor of apoptosis protein and also plays a important role in the development of several malignancies. To investigate the association between survivin promoter 31 G/C (rs9904341) polymorphism and bladder cancer (BC) risk. A total of 200 pathologically confirmed BC cases and 200 unrelated cancer-free controls were recruited in Chiayi Christian Hospital from August 2002 to May 2009. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used to determine the 31 G/C polymorphism at survivin promoter region. There was a significant difference in the frequency distribution of survivin promoter 31 G/C polymorphism in BC cases as compared to controls. Among BC cases, individuals with the C/C genotype of survivin promoter have a significantly higher prevalence of invasive (T2-T4) or high-grade (G2-G3) tumors as compared to those who carried the G/G genotype. In conclusion, our findings suggest that the survivin promoter 31 G/C polymorphism was not only associated with clinical stage and pathological grade but also involved in the development of bladder cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Huang, Z. , Chiang, Y. , Tung, M. , Wu, C. , Chen, K. , Huang, M. , Wang, Y. and Shen, C. (2013) Survivin promoter rs9904341 polymorphism is associated with tumor stage and grade in patients with bladder cancer. Advances in Bioscience and Biotechnology, 4, 1-5. doi: 10.4236/abb.2013.41001.

References

[1] Melet, A., et al. (2008) Apoptotic pathways in tumor progression and therapy. Advances in Experimental Medicine and Biology, 615, 47-79. doi:10.1007/978-1-4020-6554-5_4
[2] Reed, J.C. et al. (2001) The Survivin saga goes in vivo. The Journal of Clinical Investigation, 108, 965-969. doi:10.1172/JCI14123
[3] Sah, N.K., et al. (2006) Structural, functional and therapeutic biology of survivin. Cancer Letters, 244, 164-171. doi:10.1016/j.canlet.2006.03.007
[4] Duffy, M.J., et al. (2007) Survivin: A promising tumor biomarker. Cancer Letters, 249, 49-60. doi:10.1016/j.canlet.2006.12.020
[5] Shen, C.H., et al. (2007) Inducible nitric oxide synthase promoter poly-morphism, cigarette smoking, and urothelial carcinoma risk. Urology, 69, 1001-1006. doi:10.1016/j.urology.2007.02.028
[6] Margulis, V., et al. (2008) Survivin: a promising biomarker for detection and prognosis of bladder cancer. World Journal of Urology, 26, 59-65. doi:10.1007/s00345-007-0219-y
[7] Karam, J.A., et al. (2007) Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology, 70, 482-486. doi:10.1016/j.urology.2007.05.009
[8] Ponnelle, T., et al. (2005) Cellular localisation of survivin: Impact on the prognosis in colorectal cancer. Journal of Cancer Re-search and Clinical Oncology, 131, 504-510. doi:10.1007/s00432-005-0682-z
[9] Ulukus, E.C., et al. (2007) Survivin expression in non-small-cell lung carcinomas: Correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Applied Immunohisto-chemistry & Molecular Morphology, 15, 31-37. doi:10.1097/01.pai.0000201808.35931.78
[10] Lin, C.Y., et al. (2005) Survivin expression predicts poorer progno-sis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncology, 41, 645-654. doi:10.1016/j.oraloncology.2005.02.009
[11] Smith, S.D., et al. (2001) Urine detection of survivin and diagnosis of bladder cancer. Journal of the American Medical Association, 285, 324-328. doi:10.1001/jama.285.3.324
[12] Shariat, S.F., et al. (2004) Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Journal of Urology, 171, 626-630. doi:10.1097/01.ju.0000107826.78479.90
[13] Swana, H.S., et al. (1999) Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. The New England Journal of Medicine, 341, 452-453. doi:10.1056/NEJM199908053410614
[14] Ku, J.H., et al. (2004) Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. Journal of Urology, 171, 631-635. doi:10.1097/01.ju.0000106082.44786.3b
[15] Chiou, S.K., et al. (2003) Survivin—An anti-apoptosis protein: Its biological roles and implications for cancer and beyond. Med Sci Monit, 9, PI25-P129.
[16] Li, F., et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396, 580-584. doi:10.1038/25141
[17] Gonul, I.I., et al. (2007) Comparison of 1998 WHO/ ISUP and 1973 WHO classifications for interobserver variability in grading of papillary urothelial neoplasms of the bladder. Pathological evaluation of 258 cases. Urology International, 78, 338-344. doi:10.1159/000100839
[18] Bircan, S., et al. (2004) Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urology International, 73, 201-208. doi:10.1159/000080826
[19] Tan, T.T., et al. (2008) Therapeutic targeting of death pathways in cancer: Mechanisms for activating cell death in cancer cells. Advances in Experimental Medicine and Biology, 615, 81-104. doi:10.1007/978-1-4020-6554-5_5
[20] Coppola, J.M., et al. (2008) Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clinical Cancer Research, 14, 2492-2501. doi:10.1158/1078-0432
[21] Borbély, A.A., et al. (2007) Survivin promoter polymerphism and cervical carcino-genesis. Journal of Clinical Pathology, 60, 303-306. doi:10.1136/jcp.2006.037804
[22] Jang, J.S., et al. (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer, 60, 31-39. doi:10.1016/j.lungcan.2007.09.008
[23] Wagner, M., et al. (2008) Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leu- kemia Research, 32, 1054-1060. doi:10.1016/j.leukres.2007.11.013
[24] Cheng, Z.J., et al. (2008) Correlation of ?31G/C Polymorphisms of Survivin Promoter to Tumorigenesis of Gastric Carcinoma. Ai Zheng, 27, 258-263. doi:10.3760/cma.j.issn.1673-422X
[25] Xu, Y., et al. (2004) A mutation found in the promoter region of the human survivin gene is correlated to over- expression of survivin in cancer cells. DNA and Cell Biology, 23, 527-537. doi:10.1089/1044549041939278
[26] Hoffman, W.H., et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. The Journal of Biological Chemistry, 277, 3247-3257. doi:10.1074/ jbc.M106643200
[27] Pina-Cabral, L., et al. (2007) Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clinical and Translational Oncology, 9, 731-736. doi:10.1007/s12094-007-0130-4
[28] Schultz, I.J., et al. (2003) Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to re-currence. Anticancer Research, 23, 3327- 3331. doi:10.1111/j.1365-2567.2008.02826.x
[29] Ohsawa, I., et al. (2004) Detection of urine survivin in 40 patients with bladder cancer. Journal of Nippon Medical School, 71, 379-383. doi:10.1272/jnms.71.379
[30] Wang, H., et al. (2004) The expression and significance of survivin mRNA in urinary bladder carcinomas. Journal of Cancer Research and Clinical Oncology, 130, 487-490. doi:10.1007/s00432-004-0561-z
[31] Srivastava, K., et al. (2012) Survivin promoter-31G/C (rs9904341) poly-morphism and cancer susceptibility: A meta-analysis. Molecular Biology Reports, 39, 1509-1516. doi:10.1007/s11033-011-0889-9
[32] Wang, X., et al. (2012) Association between survivin ?31G > C promoter polymorphism and cancer risk: A meta-analysis. European Journal of Human Genetics, 20, 790-795. doi:10.1038/ejhg.2011.276

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.